Lifecore Biomedical Q1 Revenue Plunges 34% to $23.2M, Reaffirms 2026 Guidance
LFCR sits 40% above its 52-week low of $3.625.
Summary
Lifecore Biomedical reported a significant 34% year-over-year revenue decline to $23.2 million for the first quarter ended March 31, 2026, accompanied by a substantial drop in Adjusted EBITDA to $1.0 million from $5.7 million in the prior year. The net loss also slightly widened to $15.0 million. Despite these weak quarterly financial results, the company reaffirmed its full-year 2026 guidance, indicating management's confidence in a recovery or that Q1 was within expectations for their annual plan. Operational highlights included signing three new commercial site transfer programs and continued success in cost containment. Traders will be closely monitoring subsequent quarters to see if the company can deliver on its reaffirmed guidance following a challenging start to the fiscal year.
At the time of this announcement, LFCR was trading at $5.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $193.4M. The 52-week trading range was $3.63 to $8.98. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.